Naloxone injection for opioid overdose reversal

Naloxone hydrochloride injection is a medication used to rapidly reverse opioid overdose effects such as respiratory depression, sedation, and hypotension. It works as an opioid antagonist and can be given intravenously, intramuscularly, or subcutaneously.

Naloxone hydrochloride injection is indicated for:

• Complete or partial reversal of opioid-induced respiratory depression, sedation, and hypotension due to natural or synthetic opioids including propoxyphene, methadone, and mixed agonist-antagonist analgesics such as nalbuphine, pentazocine, butorphanol, and cyclazocine.
• Diagnosis of suspected or known acute opioid overdose.
• Potential adjunctive use to increase blood pressure in the management of septic shock, although its benefit in this setting is not established and requires caution.

naloxone hydrochloride

Naloxone acts by competitively binding to opioid receptor sites in the central nervous system, with the highest affinity for the mu-opioid receptor. By blocking these receptors, naloxone rapidly reverses the effects of opioids, such as slowed breathing and sedation. It does not produce opioid-like effects on its own and has no agonist activity.

General administration: Naloxone hydrochloride injection may be administered intravenously, intramuscularly, or subcutaneously. The onset of action is usually within two minutes for intravenous use, and slightly slower for intramuscular or subcutaneous routes. The duration depends on the dose and administration route, with intramuscular injections providing a longer effect than intravenous.

Monitoring and repeat dosing: Because naloxone's duration may be shorter than that of some opioids, patients should be closely monitored and additional doses administered as needed to maintain opioid reversal.

Pediatric use: Can be used in children and neonates to reverse opioid effects. Intramuscular or subcutaneous routes are not preferred due to erratic absorption. Neonates may require direct administration after delivery as naloxone effects from maternal dosing last only approximately two hours.

Postoperative opioid depression: Excessive doses may cause agitation and reversal of analgesia. Use caution with dose selection.

Contraindicated in patients with known hypersensitivity to naloxone hydrochloride or any ingredients in the formulation.

Naloxone should be used cautiously in patients physically dependent on opioids, including newborns of opioid-dependent mothers, because abrupt reversal can precipitate severe withdrawal symptoms.

Withdrawal symptoms may include body aches, diarrhea, tachycardia, fever, nausea, vomiting, sweating, irritability, shivering, abdominal cramps, and increased blood pressure. In neonates, convulsions and excessive crying may also occur.

Repeated doses may be necessary as naloxone's effect may be shorter than the opioid’s.

Naloxone is ineffective against respiratory depression from non-opioid causes and may incompletely reverse effects of partial opioid agonists or mixed agonist-antagonist drugs (e.g., buprenorphine, pentazocine), sometimes requiring higher doses.

Use caution in patients with cardiovascular disease or those who have received drugs with adverse cardiovascular effects; sudden reversal of opioids can cause serious cardiac events including arrhythmias, pulmonary edema, and cardiac arrest.

Use caution in septic shock patients due to risks such as agitation, seizures, and cardiac complications.

Common and serious adverse effects reported include:

• Cardiac events: pulmonary edema, cardiac arrest or failure, tachycardia, ventricular fibrillation and tachycardia, with some cases leading to coma, death, or encephalopathy.
• Gastrointestinal: nausea, vomiting.
• Nervous system: convulsions, paresthesia, grand mal seizures.
• Psychiatric: agitation, hallucinations, tremulousness.
• Respiratory: dyspnea, respiratory depression, hypoxia.
• Vascular: hypertension, hypotension, hot flashes, flushing.
• Skin: injection site reactions, sweating.

Abrupt opioid reversal can cause severe symptoms such as nausea, sweating, tachycardia, increased blood pressure, seizures, pulmonary edema, and cardiac arrest.

Large doses of naloxone are required to reverse buprenorphine because of its long receptor binding duration. Methohexital may reduce naloxone-induced withdrawal symptoms in opioid addicts.

Pregnancy: Animal studies have shown no teratogenic effects at high doses, but there are no adequate controlled human studies. Use during pregnancy only if clearly needed. Naloxone crosses the placenta and may precipitate withdrawal in opioid-dependent mothers and fetuses. Monitor pregnant women with hypertension closely as severe hypertension may occur during labor.

Lactation: It is unknown whether naloxone is excreted in human milk; caution is advised when administering to nursing mothers.

Protect from light by keeping the vial in the carton until ready for use.